325 related articles for article (PubMed ID: 34983540)
1. Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas.
Baptista BO; de Souza ABL; Riccio EKP; Bianco-Junior C; Totino PRR; Martins da Silva JH; Theisen M; Singh SK; Amoah LE; Ribeiro-Alves M; Souza RM; Lima-Junior JC; Daniel-Ribeiro CT; Pratt-Riccio LR
Malar J; 2022 Jan; 21(1):6. PubMed ID: 34983540
[TBL] [Abstract][Full Text] [Related]
2. B-Cell Epitope Mapping of the
Baptista BO; Souza ABL; Oliveira LS; Souza HADS; Barros JP; Queiroz LT; Souza RM; Amoah LE; Singh SK; Theisen M; Rodrigues-da-Silva RN; Riccio EKP; Totino PRR; Lima-Junior JDC; Daniel-Ribeiro CT; Pratt-Riccio LR
Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851323
[TBL] [Abstract][Full Text] [Related]
3. Humoral immune response to Plasmodium falciparum vaccine candidate GMZ2 and its components in populations naturally exposed to seasonal malaria in Ethiopia.
Mamo H; Esen M; Ajua A; Theisen M; Mordmüller B; Petros B
Malar J; 2013 Feb; 12():51. PubMed ID: 23383869
[TBL] [Abstract][Full Text] [Related]
4. Effect of hookworm infection and anthelmintic treatment on naturally acquired antibody responses against the GMZ2 malaria vaccine candidate and constituent antigens.
Amoani B; Gyan B; Sakyi SA; Abu EK; Nuvor SV; Barnes P; Sarkodie-Addo T; Ahenkorah B; Sewor C; Dwomoh D; Theisen M; Cappello M; Wilson MD; Adu B
BMC Infect Dis; 2021 Apr; 21(1):332. PubMed ID: 33832450
[TBL] [Abstract][Full Text] [Related]
5. Expression, Purification and Characterization of GMZ2'.10C, a Complex Disulphide-Bonded Fusion Protein Vaccine Candidate against the Asexual and Sexual Life-Stages of the Malaria-Causing Plasmodium falciparum Parasite.
Mistarz UH; Singh SK; Nguyen TTTN; Roeffen W; Yang F; Lissau C; Madsen SM; Vrang A; Tiendrebeogo RW; Kana IH; Sauerwein RW; Theisen M; Rand KD
Pharm Res; 2017 Sep; 34(9):1970-1983. PubMed ID: 28646324
[TBL] [Abstract][Full Text] [Related]
6. Synthetic Antigens Derived from
Pratt-Riccio LR; De Souza Perce-Da-Silva D; Da Costa Lima-Junior J; Pratt Riccio EK; Ribeiro-Alves M; Santos F; Arruda M; Camus D; Druilhe P; Oliveira-Ferreira J; Daniel-Ribeiro CT; Banic DM
Am J Trop Med Hyg; 2017 Nov; 97(5):1581-1592. PubMed ID: 29016339
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
Tamborrini M; Stoffel SA; Westerfeld N; Amacker M; Theisen M; Zurbriggen R; Pluschke G
Malar J; 2011 Dec; 10():359. PubMed ID: 22166048
[TBL] [Abstract][Full Text] [Related]
8. Synthetic TLR4 agonists enhance functional antibodies and CD4+ T-cell responses against the Plasmodium falciparum GMZ2.6C multi-stage vaccine antigen.
Baldwin SL; Roeffen W; Singh SK; Tiendrebeogo RW; Christiansen M; Beebe E; Carter D; Fox CB; Howard RF; Reed SG; Sauerwein R; Theisen M
Vaccine; 2016 Apr; 34(19):2207-15. PubMed ID: 26994314
[TBL] [Abstract][Full Text] [Related]
9. Natural antibody responses to Plasmodium falciparum MSP3 and GLURP(R0) antigens are associated with low parasite densities in malaria patients living in the Central Region of Ghana.
Amoah LE; Nuvor SV; Obboh EK; Acquah FK; Asare K; Singh SK; Boampong JN; Theisen M; Williamson KC
Parasit Vectors; 2017 Aug; 10(1):395. PubMed ID: 28835262
[TBL] [Abstract][Full Text] [Related]
10. A Pfs48/45-based vaccine to block Plasmodium falciparum transmission: phase 1, open-label, clinical trial.
Alkema M; Smit MJ; Marin-Mogollon C; Totté K; Teelen K; van Gemert GJ; van de Vegte-Bolmer M; Mordmüller BG; Reimer JM; Lövgren-Bengtsson KL; Sauerwein RW; Bousema T; Plieskatt J; Theisen M; Jore MM; McCall MBB
BMC Med; 2024 Apr; 22(1):170. PubMed ID: 38649867
[TBL] [Abstract][Full Text] [Related]
11. The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas.
Jepsen MP; Jogdand PS; Singh SK; Esen M; Christiansen M; Issifou S; Hounkpatin AB; Ateba-Ngoa U; Kremsner PG; Dziegiel MH; Olesen-Larsen S; Jepsen S; Mordmüller B; Theisen M
J Infect Dis; 2013 Aug; 208(3):479-88. PubMed ID: 23624363
[TBL] [Abstract][Full Text] [Related]
12. The GMZ2 malaria vaccine: from concept to efficacy in humans.
Theisen M; Adu B; Mordmüller B; Singh S
Expert Rev Vaccines; 2017 Sep; 16(9):907-917. PubMed ID: 28699823
[TBL] [Abstract][Full Text] [Related]
13. Plasmodium falciparum merozoite surface antigen-specific cytophilic IgG and control of malaria infection in a Beninese birth cohort.
Adamou R; Dechavanne C; Sadissou I; d'Almeida T; Bouraima A; Sonon P; Amoussa R; Cottrell G; Le Port A; Theisen M; Remarque EJ; Longacre S; Moutairou K; Massougbodji A; Luty AJF; Nuel G; Migot-Nabias F; Sanni A; Garcia A; Milet J; Courtin D
Malar J; 2019 Jun; 18(1):194. PubMed ID: 31185998
[TBL] [Abstract][Full Text] [Related]
14. The dynamics of naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs230 & Pfs48/45 in a low endemic area in Tanzania.
Bousema T; Roeffen W; Meijerink H; Mwerinde H; Mwakalinga S; van Gemert GJ; van de Vegte-Bolmer M; Mosha F; Targett G; Riley EM; Sauerwein R; Drakeley C
PLoS One; 2010 Nov; 5(11):e14114. PubMed ID: 21124765
[TBL] [Abstract][Full Text] [Related]
15. Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2.
Dejon-Agobe JC; Ateba-Ngoa U; Lalremruata A; Homoet A; Engelhorn J; Nouatin OP; Edoa JR; Fernandes JF; Esen M; Mouwenda YD; Betouke Ongwe EM; Massinga-Loembe M; Hoffman SL; Sim BKL; Theisen M; Kremsner PG; Adegnika AA; Lell B; Mordmüller B
Clin Infect Dis; 2019 Sep; 69(8):1377-1384. PubMed ID: 30561539
[TBL] [Abstract][Full Text] [Related]
16. A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children.
Bélard S; Issifou S; Hounkpatin AB; Schaumburg F; Ngoa UA; Esen M; Fendel R; de Salazar PM; Mürbeth RE; Milligan P; Imbault N; Imoukhuede EB; Theisen M; Jepsen S; Noor RA; Okech B; Kremsner PG; Mordmüller B
PLoS One; 2011; 6(7):e22525. PubMed ID: 21829466
[TBL] [Abstract][Full Text] [Related]
17. Antibody response profiles induced by Plasmodium falciparum glutamate-rich protein in naturally exposed individuals from a Brazilian area endemic for malaria.
Pratt-Riccio LR; Lima-Junior JC; Carvalho LJ; Theisen M; Espíndola-Mendes EC; Santos F; Oliveira-Ferreira J; Goldberg AC; Daniel-Ribeiro CT; Banic DM
Am J Trop Med Hyg; 2005 Dec; 73(6):1096-103. PubMed ID: 16354819
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of the profiles of IgG subclass-specific responses to Plasmodium falciparum apical membrane antigen-1 and merozoite surface protein-1 in naturally exposed individuals living in malaria hypoendemic settings, Iran.
Rouhani M; Zakeri S; Mehrizi AA; Djadid ND
Malar J; 2015 Feb; 14():58. PubMed ID: 25652589
[TBL] [Abstract][Full Text] [Related]
19. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.
Singh SK; Thrane S; Janitzek CM; Nielsen MA; Theander TG; Theisen M; Salanti A; Sander AF
Vaccine; 2017 Jun; 35(30):3726-3732. PubMed ID: 28578824
[TBL] [Abstract][Full Text] [Related]
20. Antibody Responses Against
Matos ADS; Rodrigues-da-Silva RN; Soares IF; Baptista BO; de Souza RM; Bitencourt-Chaves L; Totino PRR; Sánchez-Arcila JC; Daniel-Ribeiro CT; López-Camacho C; Reyes-Sandoval A; Pratt-Riccio LR; Lima-Junior JDC
Front Immunol; 2019; 10():2230. PubMed ID: 31620136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
